Callie’s Apothecary — Alabama’s First Legal Medical Cannabis Sale

Last verified: May 2026

Why Callie’s Was First

Callie’s Apothecary’s standing as Alabama’s first operational medical-cannabis dispensary was the product of three converging factors:

• RJK Holdings AL was among the three dispensary licensees that survived ALJ Bernard Harwood’s 106-page ruling in late 2025 and was awarded a license by AMCC on December 11, 2025.
• RJK Holdings completed its 28-day post-award compliance window, paid the $40,000 license fee, and was formally issued its license on January 8, 2026.
• RJK’s Montgomery storefront was build-out-ready ahead of competitors. CCS of Alabama and GP6 Wellness completed their licensing but had longer build-out timelines.

The Pharmacy Aesthetic — Why "Apothecary"

Callie’s name and brand are deliberately pharmacy-coded. The interior layout, the consultation rooms, the staff training, and the dispensing protocol are all modeled on pharmacy operations rather than retail-cannabis dispensary models from recreational states. AMCC Chair Dr. Sam Blakemore — himself a pharmacist — visited the location in early April 2026 and told local press the visit "put me at home; it reminded me of being back at a pharmacy."

The pharmacy aesthetic is consistent with the Compassion Act’s allowed-product slate: tablets, capsules, tinctures, gels, suppositories, transdermal patches, and nebulizer solution — products that resemble pharmaceutical formulations rather than the flower / vape / edible / pre-roll product mix typical of recreational dispensaries. The pharmacy framing was instrumental to the political coalition that produced the 2021 bill: the framing answers conservative concerns about "recreational creep" and child appeal.

The April 9, 2026 Announcement

On April 9, 2026, Dr. Blakemore publicly announced the May 4 opening date. The announcement was the first definitive opening date in the program’s history — previous dates had been speculative or had slipped due to litigation, build-out delays, or compliance reviews. Blakemore’s announcement was understood as a signal that AMCC was confident the launch would proceed without further legal interruption.

The Practical Mechanics of a Compassion-Act Sale

A patient’s first visit to Callie’s on May 4 followed the regulated process the Compassion Act prescribed:

1. Patient arrived with valid Alabama medical-cannabis card issued by an AMCC-registered certifying physician.
2. Patient presented government photo identification matching the medical-cannabis card.
3. Dispensary staff verified the patient’s registration through the state seed-to-sale tracking system, including verifying that the patient was not over the 70-day supply limit.
4. Pharmacist consulted with the patient about dosing, drug-drug interactions, contraindications, and product selection. The consultation requirement is unusual among U.S. dispensary models — most recreational dispensaries do not require pharmacist consultation.
5. Patient selected from the available product slate: tablets, capsules, tinctures, gels, suppositories, transdermal patches, nebulizer solution.
6. Dispensary checked dose against the daily THC cap (50 mg adult default, up to 75 mg with physician approval).
7. Sale completed in cash or debit — no credit cards (federal banking restrictions). 9% Compassion Act excise tax + state sales tax + Montgomery municipal sales tax applied.
8. Sale logged in seed-to-sale system, with patient’s 70-day-supply tracker updated in real time.

The Other License Holders

As of Callie’s May 4 opening, the other AMCC dispensary licensees were at various stages of build-out:

• CCS of Alabama — license issued Jan 8, 2026; build-out continuing as of May 2026.
• GP6 Wellness — license issued Jan 8, 2026; build-out continuing.
• Yellowhammer Medical Dispensaries — license stayed pending Capitol Medical’s ongoing administrative challenge as of May 2026.
• Five integrated-facility licenses — remain in administrative-hearing review under ALJ Harwood. When issued, the integrated facilities would dramatically expand statewide footprint (each authorized up to 5 storefronts).

The Five-Year Gap in Context

Alabama’s five-year gap from enactment to first sale is the longest of any modern U.S. medical-cannabis program. For comparison:

• Pennsylvania (PL 16-2016): enacted April 2016, first sale February 2018 — 22 months.
• Florida (Amendment 2): enacted November 2016, first sale July 2017 — 8 months.
• Ohio (HB 523): enacted June 2016, first sale January 2019 — 31 months.
• Maryland (HB 1101): enacted May 2014, first sale December 2017 — 43 months.
• Mississippi (Miss. Code § 41-137-1): enacted February 2022, first sale January 2023 — 11 months.
• Alabama (SB 46): enacted May 2021, first sale May 2026 — 59 months.

The Alabama gap reflects the particular convergence of three voided AMCC license rounds, extensive litigation in state and federal courts, an Alabama Court of Civil Appeals reversal, the failure of legislative reform (SB 72), and the documented procedural irregularities later confirmed by the March 2026 Examiners audit.

What the First Sale Symbolizes

The Callie’s opening symbolizes the formal end of the Compassion Act implementation phase and the beginning of the operational phase. From May 4 forward, the program’s success will be measured by patient access, product availability, certifying-physician adoption, and the path of the still-pending integrated-facility licenses. The litigation infrastructure of 2023–2025 has settled but is not fully resolved — the Yellowhammer stay and the pending integrated-facility hearings remain in front of ALJ Harwood and AMCC.